Frontiers in Cell and Developmental Biology (May 2022)

Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy

  • Hong Dai,
  • Hong Dai,
  • Razack Abdullah,
  • Razack Abdullah,
  • Xiaoqiu Wu,
  • Xiaoqiu Wu,
  • Fangfei Li,
  • Fangfei Li,
  • Fangfei Li,
  • Yuan Ma,
  • Yuan Ma,
  • Yuan Ma,
  • Aiping Lu,
  • Aiping Lu,
  • Aiping Lu,
  • Ge Zhang,
  • Ge Zhang,
  • Ge Zhang

DOI
https://doi.org/10.3389/fcell.2022.855474
Journal volume & issue
Vol. 10

Abstract

Read online

Pancreatic cancer (PC) is one of the most lethal cancers with an almost 10% 5-year survival rate. Because PC is implicated in high heterogeneity, desmoplastic tumor-microenvironment, and inefficient drug-penetration, the chemotherapeutic strategy currently recommended for the treatment of PC has limited clinical benefit. Nucleic acid-based targeting therapies have become strong competitors in the realm of drug discovery and targeted therapy. A vast evidence has demonstrated that antibody-based or alternatively aptamer-based strategy largely contributed to the elevated drug accumulation in tumors with reduced systematic cytotoxicity. This review describes the advanced progress of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), messenger RNA (mRNAs), and aptamer-drug conjugates (ApDCs) in the treatment of PC, revealing the bright application and development direction in PC therapy.

Keywords